Research Leadership The Australasian Leukaemia & Lymphoma Group (ALLG) has a strong history of clinical trial leadership and collaborative research initiatives since 1973, making it an influential partner for organizations seeking to expand their presence in blood cancer research and treatment development markets.

Data Resources With the largest real-world acute myeloid leukemia data registry in Australia and New Zealand, ALLG offers valuable data assets that can support pharma and biotech companies in clinical trial design, biomarker discovery, and real-world evidence generation.

Strategic Collaborations Recent collaborations, including with Mendus AB on AML treatment trials, highlight opportunities to engage with ALLG for joint studies, access to patient populations, and development of innovative therapies in blood cancers.

Global Presence Participation in major events like ASH 2025 and Blood 2025 Conference demonstrates ALLG’s active engagement in the global hematology research community, offering avenues for partnerships, sponsorships, and thought leadership visibility.

Funding & Growth While current revenue ranges from $1 million to $10 million, allg’s strategic investments in research and collaborative projects position it as a promising partner for organizations looking to expand into the Australian and New Zealand blood cancer research markets.